Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 178 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Doxycycline (Oracea) Clear all
Terminated Phase 4 Interventional Results available

Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis

NCT02623959
View directory record Official record
Conditions
Advanced Cancers, Malignant Pleural Effusions
Interventions
Questionnaires, Fentanyl Patch, Fentanyl (IV), Saline, Doxycycline, Phone Calls
Behavioral · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 2Phase 3 Interventional

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

NCT04349410
View directory record Official record
Conditions
CoVid 19 Positive
Interventions
Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
Drug
Lead sponsor
The Camelot Foundation
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Results available

The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

NCT01160640
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Ceftriaxone, Doxycycline, Metronidazole, Placebo Oral Capsule
Drug
Lead sponsor
Harold Wiesenfeld
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 1, 2026, 8:07 AM EDT
Terminated Phase 2 Interventional Results available

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

NCT02874430
View directory record Official record
Conditions
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma
Interventions
Metformin Hydrochloride, Doxycycline
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lipids of the Human Tear Film and Their Effect on Tear Stability

NCT00803452
View directory record Official record
Conditions
Blepharitis
Interventions
doxycycline, azithromycin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 1, 2026, 8:07 AM EDT
Recruiting Phase 1 Interventional

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

NCT07290244
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions
ER-100 epigenetic therapy
Genetic
Lead sponsor
Life Biosciences Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Glendale, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Recruiting Phase 4 Interventional

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections

NCT06738407
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infections (STIs)
Interventions
Doxycycline hyclate delayed released 200 mg, Doxycycline hyclate delayed released 200 mg weekly, Per standard of care with quarterly STI testing/treatment and sexual health counseling
Drug · Other
Lead sponsor
Westat
Other
Eligibility
13 Years to 29 Years · Female only
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

NCT01426269
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Metronidazole, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Santa Monica, California • Coral Gables, Florida • Corbin, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy

NCT00917553
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
doxycycline monohydrate, Placebo
Drug
Lead sponsor
Thomas Gardner
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy

NCT00511875
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
doxycycline monohydrate, placebo
Drug
Lead sponsor
Thomas Gardner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Not applicable Interventional

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris

NCT02905851
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Feedback group, Non Feedback group
Other
Lead sponsor
University of California, Davis
Other
Eligibility
15 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 1, 2026, 8:07 AM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers

NCT04850313
View directory record Official record
Conditions
Bacterial Corneal Ulcer
Interventions
ProProKera Plus®
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 1, 2026, 8:07 AM EDT
Recruiting No phase listed Observational

Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions

NCT03465774
View directory record Official record
Conditions
Pleural Neoplasm
Interventions
Doxycycline, Indwelling Catheter, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
Drug · Device · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Completed No phase listed Observational

Risk of Acute Liver Injury in Users of Antimicrobials

NCT01434173
View directory record Official record
Conditions
Drug-Induced Liver Injury
Interventions
Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,299,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Many Locations, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 1, 2026, 8:07 AM EDT
Terminated Phase 3 Interventional Results available

D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

NCT03558984
View directory record Official record
Conditions
Surgical Site Infection, Sternal Infection, Cardiac Surgery
Interventions
D-PLEX, Standard of Care
Drug · Other
Lead sponsor
PolyPid Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Huston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Not listed Early Phase 1 Interventional

CTCL Directed Therapy

NCT03116659
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
Doxycycline, Imiquimod
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
30 Years to 89 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 1, 2026, 8:07 AM EDT
Recruiting Phase 4 Interventional

Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams

NCT07164131
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Doxycycline, Azithromycin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg

NCT00648180
View directory record Official record
Conditions
Healthy
Interventions
Doxycycline Monohydrate Tablets 100 mg, Adoxa Tablets 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 1, 2026, 8:07 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

NCT01917721
View directory record Official record
Conditions
Kawasaki Disease, Coronary Aneurysm
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Month to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 4 Interventional Results available

Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

NCT03608774
View directory record Official record
Conditions
Anal Chlamydia Infection
Interventions
Azithromycin, Doxycycline, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Not applicable Interventional Results available

Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients

NCT01112059
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Doxycycline, placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 3 Interventional Results available

D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

NCT04233424
View directory record Official record
Conditions
Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Interventions
D-PLEX, Standard of Care (SoC)
Drug
Lead sponsor
PolyPid Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Sheffield, Alabama • Los Angeles, California • Redding, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Recruiting Phase 4 Interventional

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

NCT04207931
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Topical steroid class I-II, Triamcinolone Acetonide, Doxycyline, Minoxidil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 1, 2026, 8:07 AM EDT
Completed Phase 3 Interventional Results available

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

NCT00351273
View directory record Official record
Conditions
Arthritis, Reactive, Reiter Disease
Interventions
Doxycycline and Rifampin, Azithromycin and Rifampin, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Tampa, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 1, 2026, 8:07 AM EDT